Tofacitinib-话题@MedSci

#Tofacitinib#

11篇内容 | 682人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2159378, encodeId=790921593e898, content=<a href='/topic/show?id=b0ca1e6220a' target=_blank style='color:#2F92EE;'>#Tofacitinib#</a>能够有效抑制与SSc相关的IFN激活基因表达，特别是在<a href='/topic/show?id=6dab540565f' target=_blank style='color:#2F92EE;'>#成纤维细胞#</a>和<a href='/topic/show?id=adbd1066e613' target=_blank style='color:#2F92EE;'>#角质形成细胞#</a>中。, objectTitle=JCI Insight：托法替尼阻断皮肤成纤维细胞和角质形成细胞中干扰素调节的生物标志物基因, objectType=article, longId=793296, objectId=4452e93296b2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668019396776_4754896.png, objectUrl=/article/show_article.do?id=4452e93296b2, replyNumber=0, likeNumber=51, createdTime=2023-09-24, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4452e93296b2, moduleTitle=JCI Insight：托法替尼阻断皮肤成纤维细胞和角质形成细胞中干扰素调节的生物标志物基因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4452e93296b2)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1752021, encodeId=b4941e5202187, content=<a href='/topic/show?id=b0ca1e6220a' target=_blank style='color:#2F92EE;'>#Tofacitinib#</a>, objectTitle=J Am Acad Dermatol：外用JAK-STAT抑制剂Tofacitinib有效减少非特应性皮炎慢性瘙痒, objectType=article, longId=301104, objectId=bf1030110428, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf1030110428, replyNumber=0, likeNumber=33, createdTime=2023-01-04, rootId=0, userName=ysjykql, userId=e50836414432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf1030110428, moduleTitle=J Am Acad Dermatol：外用JAK-STAT抑制剂Tofacitinib有效减少非特应性皮炎慢性瘙痒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf1030110428)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752020, encodeId=ef0e1e5202072, content=<a href='/topic/show?id=b0ca1e6220a' target=_blank style='color:#2F92EE;'>#Tofacitinib#</a>, objectTitle=Nat Commun：Tofacitinib治疗系统性红斑狼疮的1期临床试验结果, objectType=article, longId=212458, objectId=485a21245897, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=485a21245897, replyNumber=0, likeNumber=38, createdTime=2021-10-13, rootId=0, userName=ysjykql, userId=e50836414432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=485a21245897, moduleTitle=Nat Commun：Tofacitinib治疗系统性红斑狼疮的1期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=485a21245897)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752019, encodeId=a50c1e5201914, content=<a href='/topic/show?id=b0ca1e6220a' target=_blank style='color:#2F92EE;'>#Tofacitinib#</a>, objectTitle=XELJANZ（tofacitinib）治疗强直性脊柱炎（AS）：III期研究取得阳性结果, objectType=article, longId=203133, objectId=529b20313392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=529b20313392, replyNumber=0, likeNumber=34, createdTime=2021-07-02, rootId=0, userName=ysjykql, userId=e50836414432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=529b20313392, moduleTitle=XELJANZ（tofacitinib）治疗强直性脊柱炎（AS）：III期研究取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=529b20313392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752018, encodeId=70f91e52018e9, content=<a href='/topic/show?id=b0ca1e6220a' target=_blank style='color:#2F92EE;'>#Tofacitinib#</a>, objectTitle=Clin Gastroenterology H： Tofacitinib诱导疗法可在3天内减轻UC患者的症状, objectType=article, longId=157888, objectId=b0b215e8885a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0b215e8885a, replyNumber=0, likeNumber=34, createdTime=2019-10-27, rootId=0, userName=ysjykql, userId=e50836414432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0b215e8885a, moduleTitle=Clin Gastroenterology H： Tofacitinib诱导疗法可在3天内减轻UC患者的症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0b215e8885a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752017, encodeId=c5ba1e52017f4, content=<a href='/topic/show?id=b0ca1e6220a' target=_blank style='color:#2F92EE;'>#Tofacitinib#</a>, objectTitle=JAMA Dermatol：托法替尼（Tofacitinib）——白癜风治疗的新希望, objectType=article, longId=53256, objectId=8a4653256e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a4653256e4, replyNumber=0, likeNumber=34, createdTime=2015-09-27, rootId=0, userName=ysjykql, userId=e50836414432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a4653256e4, moduleTitle=JAMA Dermatol：托法替尼（Tofacitinib）——白癜风治疗的新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a4653256e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752016, encodeId=77f11e52016fd, content=<a href='/topic/show?id=b0ca1e6220a' target=_blank style='color:#2F92EE;'>#Tofacitinib#</a>, objectTitle=辉瑞潜在重磅药物tofacitinib 2个III期研究达主要终点, objectType=article, longId=25277, objectId=4107252e7fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4107252e7fd, replyNumber=0, likeNumber=37, createdTime=2014-07-23, rootId=0, userName=ysjykql, userId=e50836414432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4107252e7fd, moduleTitle=辉瑞潜在重磅药物tofacitinib 2个III期研究达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4107252e7fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752014, encodeId=4f681e520144d, content=<a href='/topic/show?id=b0ca1e6220a' target=_blank style='color:#2F92EE;'>#Tofacitinib#</a>, objectTitle=FDA批准tofacitinib治疗类风湿关节炎, objectType=article, longId=10908, objectId=07911090866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07911090866, replyNumber=0, likeNumber=33, createdTime=2013-03-13, rootId=0, userName=ysjykql, userId=e50836414432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07911090866, moduleTitle=FDA批准tofacitinib治疗类风湿关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07911090866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752013, encodeId=3ff21e5201397, content=<a href='/topic/show?id=b0ca1e6220a' target=_blank style='color:#2F92EE;'>#Tofacitinib#</a>, objectTitle=NEJM：新药Tofacitinib具有治疗类风湿性关节炎的疗效, objectType=article, longId=8928, objectId=d169892874, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d169892874, replyNumber=0, likeNumber=45, createdTime=2013-05-20, rootId=0, userName=ysjykql, userId=e50836414432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d169892874, moduleTitle=NEJM：新药Tofacitinib具有治疗类风湿性关节炎的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d169892874)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752015, encodeId=ab2a1e52015d2, content=<a href='/topic/show?id=b0ca1e6220a' target=_blank style='color:#2F92EE;'>#Tofacitinib#</a>, objectTitle=A&R: 接受甲氨蝶呤治疗的类风湿关节炎患者合用Tofacitinib（CP-690,550）的临床随机研究, objectType=article, longId=17915, objectId=dbba1e915b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbba1e915b2, replyNumber=0, likeNumber=36, createdTime=2013-11-22, rootId=0, userName=ysjykql, userId=e50836414432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbba1e915b2, moduleTitle=A&R: 接受甲氨蝶呤治疗的类风湿关节炎患者合用Tofacitinib（CP-690,550）的临床随机研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbba1e915b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752012, encodeId=fd581e5201229, content=<a href='/topic/show?id=b0ca1e6220a' target=_blank style='color:#2F92EE;'>#Tofacitinib#</a>, objectTitle=辉瑞潜在重磅药物tofacitinib下周面临FDA专家小组关键性表决, objectType=article, longId=5996, objectId=78a6599680, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78a6599680, replyNumber=0, likeNumber=33, createdTime=2012-11-07, rootId=0, userName=ysjykql, userId=e50836414432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78a6599680, moduleTitle=辉瑞潜在重磅药物tofacitinib下周面临FDA专家小组关键性表决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78a6599680)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

(审核中...)

前往app查看评论内容

#Tofacitinib#能够有效抑制与SSc相关的IFN激活基因表达，特别是在#成纤维细胞#和#角质形成细胞#中。

JCI Insight：托法替尼阻断皮肤成纤维细胞和角质形成细胞中干扰素调节的生物标志物基因

2023-09-24发表于上海

ysjykql (审核中...)

前往app查看评论内容

#Tofacitinib#

J Am Acad Dermatol：外用JAK-STAT抑制剂Tofacitinib有效减少非特应性皮炎慢性瘙痒

2023-01-04

ysjykql (审核中...)

前往app查看评论内容

#Tofacitinib#

Nat Commun：Tofacitinib治疗系统性红斑狼疮的1期临床试验结果

2021-10-13

ysjykql (审核中...)

前往app查看评论内容

#Tofacitinib#

XELJANZ（tofacitinib）治疗强直性脊柱炎（AS）：III期研究取得阳性结果

2021-07-02

ysjykql (审核中...)

前往app查看评论内容

#Tofacitinib#

Clin Gastroenterology H： Tofacitinib诱导疗法可在3天内减轻UC患者的症状

2019-10-27

ysjykql (审核中...)

前往app查看评论内容

#Tofacitinib#

JAMA Dermatol：托法替尼（Tofacitinib）——白癜风治疗的新希望

2015-09-27

ysjykql (审核中...)

前往app查看评论内容

#Tofacitinib#

辉瑞潜在重磅药物tofacitinib 2个III期研究达主要终点

2014-07-23

ysjykql (审核中...)

前往app查看评论内容

#Tofacitinib#

FDA批准tofacitinib治疗类风湿关节炎

2013-03-13

ysjykql (审核中...)

前往app查看评论内容

#Tofacitinib#

NEJM：新药Tofacitinib具有治疗类风湿性关节炎的疗效

2013-05-20

ysjykql (审核中...)

前往app查看评论内容

#Tofacitinib#

A&R: 接受甲氨蝶呤治疗的类风湿关节炎患者合用Tofacitinib（CP-690,550）的临床随机研究

2013-11-22

ysjykql (审核中...)

前往app查看评论内容

#Tofacitinib#

辉瑞潜在重磅药物tofacitinib下周面临FDA专家小组关键性表决

2012-11-07

科室
- - 订阅+
  - 更多科室
工具
服务